Research programme: recombinant fusion proteins - Wyeth

Drug Profile

Research programme: recombinant fusion proteins - Wyeth

Alternative Names: GPG 290; GPIb290/2V-Ig

Latest Information Update: 10 Aug 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wyeth
  • Class Glycoproteins; Recombinant fusion proteins
  • Mechanism of Action Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute coronary syndromes; Thrombosis

Most Recent Events

  • 10 Aug 2009 Discontinued - Preclinical for Acute coronary syndromes in USA (unspecified route)
  • 10 Aug 2009 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
  • 07 Jun 2006 A preclinical study has been added to the adverse events and Thromboses pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top